Mineralys Therapeutics . Quarterly Income Statements Chart
Quarterly
|
Annual
Mineralys Therapeutics . Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | |||||||||||
| research and development | 38,278,000 | 37,879,000 | 44,569,000 | 53,985,000 | 39,273,000 | 30,754,000 | 23,685,000 | 22,499,000 | 11,884,000 | 12,293,000 | |
| general and administrative | 8,468,000 | 6,568,000 | 7,198,000 | 6,121,000 | 5,895,000 | 4,608,000 | 4,026,000 | 3,774,000 | 3,851,000 | 2,645,000 | |
| total operating expenses | 46,746,000 | 44,447,000 | 51,767,000 | 60,106,000 | 45,168,000 | 35,362,000 | 27,711,000 | 26,273,000 | 15,735,000 | 14,938,000 | |
| income from operations | -46,746,000 | -44,447,000 | -51,767,000 | -60,106,000 | -45,168,000 | -35,362,000 | -27,711,000 | -26,273,000 | -15,735,000 | -14,938,000 | |
| yoy | 3.49% | 25.69% | 86.81% | 128.77% | 187.05% | 136.73% | |||||
| qoq | 5.17% | -14.14% | -13.87% | 33.07% | 27.73% | 27.61% | 5.47% | 66.97% | 5.34% | ||
| operating margin % | |||||||||||
| interest income | 3,474,000 | 2,239,000 | 2,809,000 | 3,774,000 | 4,152,000 | 3,853,000 | 3,321,000 | 3,513,000 | 3,593,000 | 2,329,000 | |
| other income | -2,000 | -3,000 | 12,000 | -10,000 | 2,000 | 1,000 | 1,000 | 1,000 | 1,000 | ||
| total other income | 3,472,000 | 2,236,000 | 2,821,000 | 3,764,000 | 4,154,000 | 3,854,000 | 3,322,000 | 3,513,000 | 3,594,000 | 2,330,000 | |
| net income | -43,274,000 | -42,211,000 | -48,946,000 | -56,342,000 | -41,014,000 | -31,508,000 | -24,389,000 | -22,760,000 | -12,141,000 | -12,608,000 | |
| yoy | 5.51% | 33.97% | 100.69% | 147.55% | 237.81% | 149.90% | |||||
| qoq | 2.52% | -13.76% | -13.13% | 37.37% | 30.17% | 29.19% | 7.16% | 87.46% | -3.70% | ||
| net income margin % | |||||||||||
| net income per share | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.7 | -0.63 | -0.57 | -0.31 | -0.51 | |
| weighted-average shares used for eps calculation | 65,451,297 | 53,163,551 | 48,539,795 | 49,815,186 | 49,356,287 | 44,900,755 | 36,188,254 | 39,930,748 | 39,754,981 | 24,764,469 | |
We provide you with 20 years income statements for Mineralys Therapeutics . stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Mineralys Therapeutics . stock. Explore the full financial landscape of Mineralys Therapeutics . stock with our expertly curated income statements.
The information provided in this report about Mineralys Therapeutics . stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.